By Neal Rouzier, MD This is the last and final newsletter before the upcoming Hormones and Beyond 2021. I hope that you have enjoyed the commentary of these newsletters. They are an introduction as to what will be presented at Hormones and Beyond in 2 weeks. My primary focus on Friday will address reversal ofDETAIL
By Neal Rouzier, MD Recently, a new cholesterol lowering drug was approved in the U.K. The press-release heralded Inclisiran, simply another PCSK-9 inhibitor, to be a game changer as it will save thousands of lives by lowering cholesterol. No, there are no outcome studies yet, only studies that demonstrate it lowers serum cholesterol 50% moreDETAIL
Controlling HgBA1C with Medications Does not Make Diabetes Disappear – it Lowers the Surrogate Marker HgBA1C
By Neal Rouzier, MD My goal and intent of Hormones and Beyond 2021 is to introduce new and different concepts of insulin resistance and how it pertains to the development of CVD and cancer. Although the pathophysiology is simple, the treatment and reversal of the disease is what is so confusing, complex, misunderstood, and ignored.DETAIL
Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients
Recommended Pre-Reading: Treating T3 Deficiency, The Evidence You Need Interested in monthly webinars? Upgrade your Membership SCENARIO: A 59 y/o female with CVD is referred by her friend for evaluation of hypothyroidism. Laboratory tests consistently show a mildly elevated TSH and normal Free T4. Despite multiple attempts to try to get her PMD to prescribe a trialDETAIL
More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion and FINALLY the AACE releases a revised statement on Thyroid Treatment
Recommended Pre-Reading: Treating T3 Deficiency: If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients? SCENARIO: A 45 y/o female with persistent symptoms of fatigue, low energy, depression, presents for evaluation of her thyroid hormone therapy. She is referred by her friendDETAIL
Treating T3 Deficiency: If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients?
Recommended Pre-Reading: Treating T3 Deficiency, The Evidence You Need SCENARIO: Your 41 y/o PCOS patient that is optimized on thyroid returns with concerns that her PMD does not like/approve of DTE. She notes that she is finally feeling well and experiencing success with weight loss. The PMD also is upset with the suppressed TSH levelDETAIL
CVD: Could all the Medicines that we Prescribe, Including Statins, be Increasing the Risk of Cancer?
By Neal Rouzier, MD CVD is the # 1 killer in the U.S. and worldwide. The medical literature and pharmaceutical industry has led us to believe in the cholesterol-centric model in preventing CVD. Unfortunately, utilizing cholesterol-lowering medication has only led to a 1-3% absolute risk reduction (ARR) in CVD and mortality. Not very impressive forDETAIL
By Neal Rouzier, MD As clinicians we try to be problem solvers. It is part of our training, try to figure out what’s wrong, and then to fix it. Problem solved. However, what should we do if what we are doing isn’t working? Keep doing the same thing? What if the patient does not getDETAIL
Editorial by Neal Rouzier, MD DON'T BE LED ASTRAY Recently the medical community has undergone criticism for journalistic articles and medical studies that promote one drug or treatment over another. There are often political or economic gains behind the purpose or results of the studies, which leads to inappropriate and biased conclusions or recommendations inDETAIL
By Dana Burnett, M.Ed. Our goal for Part 1: Discover the Power of BHRT of the four part workshop series is to make you immediately able to start seeing patients who might benefit from the treatment. Parts II, III, and IV build on this foundation and add complexity, but Part I is to get youDETAIL